What are the opening hours?

Monday 9am - 8pm Tuesday 9am - 8pm Wednesday 9am - 8pm Thursday 9am - 8pm Friday 9am - 8pm Saturday 9am - 2pm

Dr Vinayak S Hiremath

Home
India
Kochi
Dr Vinayak S Hiremath

Dr Vinayak Hiremath MBBS,MD,MRCP(UK),MRCP(Endocrinology & Diabetology),IMMUNOLOGY(Harvard University

23/04/2026

An absolute honour to be invited by the IMA Madhya Kerala Branch this evening for a scientific address on Mounjaro (Tirzepatide) & the Obesity Paradigm — the dual-agonist era in metabolic medicine. 🩺

A packed auditorium, thoughtful senior colleagues, sharp questions, and the kind of energy that reminds you why clinical medicine is best practised in conversation with peers.

Deeply grateful to Dr. M. N. Menon, State President, IMA Kerala for the warm felicitation — and to every physician who stayed back to discuss cases, dosing strategies, and the practical realities of translating trial data to our OPDs. These are the conversations that move the needle for our patients.

Thank you Eli Lilly for the scientific platform and for continuing to invest in clinician education in this rapidly evolving space.

As obesity pharmacotherapy enters a genuinely transformative chapter — with tirzepatide (and soon retatrutide) redefining what we thought achievable — the responsibility on us as physicians is only growing: to prescribe with evidence, to individualise with judgment, and to never forget that the molecule is only as good as the clinician wielding it.

Onward. 🙏

Dr. Vinayak S Hiremath

15/04/2026

🌼 വിഷു ആശംസകൾ | Happy Vishu 2026 🪔

May the golden glow of Kani Konna and the light of the Nilavilakku bring you and your family a year filled with good health, prosperity, and happiness.

This Vishu, let us also remember — true wealth begins with good health. Invest in your well-being, nourish your body, and take that step towards a healthier you.

Wishing everyone a blessed and joyful Vishu! 🙏

#വിഷു KeralaFestival HealthIsWealth MetabolicHealth Endocrinology DrVinayakHiremath KMKHospital Kodungallur NorthParavur Ernakulam Thrissur KeralaDoctors FestiveWishes DiabetesCare ObesitySpecialist

13/04/2026

Thrilled to share that both our abstracts have been accepted for Poster Presentation at the 33rd European Congress on Obesity (ECO 2026), Istanbul, 12–15 May!

📌 #0563 — Metabolic health beyond body mass index: prevalence and determinants of metabolically unhealthy obesity in an urban Indian adult cohort

📌 #0565 — Effectiveness of a Smartphone-Based Food Journaling App on Reducing Central Obesity in Adults Living with Obesity: A Randomized Controlled Trial

Grateful for the opportunity to present Indian data on a global platform. Looking forward to the discussions in Istanbul! 🇹🇷

If anyone from India is planning to attend ECO 2026, do ping me — would be great to connect and travel together! 🙌

MetabolicHealth EASO ObesityMedicine PosterPresentation IndianResearch ClinicalResearch EndocrinologyResearch BodyComposition FoodJournaling MetabolicSyndrome BeyondBMI ObesityInIndia SCOPECertified GlobalHealth MedTwitter EndoTwitter

05/04/2026

✝️ Wishing you and your loved ones a blessed and joyful Easter! 🐣🌷

May this season of renewal bring you health, happiness, and hope. Just as spring breathes new life into the world, may you find renewed strength, peace, and well-being in every step of your journey.

From my family to yours — Happy Easter 2026! 🙏

EasterSunday SeasonOfRenewal HealthAndHope SpringVibes EasterBlessings FestiveSeason DrVinayakHiremath EndocrinologyKerala MetabolicHealth DoctorsOfInstagram KeralaDoctor KMKHospital Kodungallur NorthParavur Ernakulam HealthcareIndia WellnessJourney FaithAndHealth MedicalCommunity DoctorsLife

01/04/2026

💉 Imagine taking insulin just ONCE a week.
No, this isn’t a dream.

It’s FDA-approved. It’s real. It’s happening NOW.

Meet AWIQLI® — the FIRST and ONLY once-weekly basal insulin for Type 2 Diabetes.

Here’s what this means for millions of people:
❌ No more daily pricks
❌ No more 365 injections a year

✅ Just 52. Once a week. Same day. Done.
That’s an 86% reduction in injection burden.

The science behind it? ROCK SOLID.

The ONWARDS programme — 4 Phase 3a RCTs, ~2,680 adults — proved:
→ Superior or non-inferior HbA1c reduction vs daily insulins
→ Safety profile at par with daily basal insulin class
→ Works in insulin-naïve AND insulin-experienced patients

This isn’t just convenience.
This is better adherence.
This is fewer complications.
This is a better LIFE for people with diabetes.

💬 Tag someone living with diabetes who NEEDS to see this.

📌 SAVE this post — you’ll want to come back to it.

🔔 Follow for evidence-based diabetes & metabolic health updates that actually matter.

📋 Disclaimer: For educational and awareness purposes only. Awiqli® is a product of Novo Nordisk. This post is not sponsored. Always consult your endocrinologist or diabetologist for personalised treatment decisions.

DiabetesCare DiabetesAwareness FDAApproved DiabetesManagement Endocrinology InsulinTherapy DiabetesEducation MetabolicHealth NovoNordisk ONWARDSTrial BasalInsulin DiabetesBreakthrough DoctorsOfInstagram MedicalEducation EvidenceBasedMedicine DrVinayak DiabetesMellitus T2DM InsulinResistance GlycemicControl HbA1c PatientCare DiabetesIndia MedEd

26/03/2026

🚨 GOVERNMENT ALERT: GLP-1 Weight Loss Drugs — Major Crackdown in India

The Drugs Controller of India has officially stepped in.

On March 24, 2026, the Ministry of Health & Family Welfare issued a formal notification via PIB Delhi — intensifying regulatory surveillance over the entire GLP-1 (semaglutide/tirzepatide) supply chain.

Here’s what happened:

🔴 49 entities raided — online pharmacy warehouses, drug wholesalers, retailers, wellness clinics & slimming centres audited across India

🔴 Misleading ads BANNED — a March 10 advisory now prohibits all surrogate advertisements and indirect promotion of these drugs

🔴 SPECIALISTS ONLY — the government has reiterated that GLP-1 drugs in India are approved ONLY for prescription by:
→ Endocrinologists
→ Internal Medicine Specialists
→ Cardiologists (for specific indications)

🔴 Non-compliance = license cancellation, penalties & prosecution under applicable laws

Why does this matter to YOU?

These are powerful medications — not lifestyle supplements. When taken without proper medical supervision, they can cause serious adverse effects including severe GI complications, pancreatitis, gallbladder disease, and metabolic derangements.

The government’s message is clear: DO NOT buy these drugs from online platforms, wellness clinics, or without a specialist’s prescription.

As a specialist who prescribes GLP-1 therapy daily, I welcome this move. Patient safety must always come first — above profits, above convenience, above shortcuts.

If you’re on semaglutide or considering it:
✅ Consult your Endocrinologist — not a wellness coach
✅ Don’t self-medicate based on social media advice
✅ Your specialist will choose the right drug, dose & brand
✅ Regular monitoring is essential

Save this. Share it. Someone in your circle needs to see this. 💾

GLP1ReceptorAgonist DrugSafety PatientSafety DrugsControllerIndia PIBDelhi HealthAlert IndiaHealth GovtOfIndia RegulatoryUpdate ObesityMedicine Endocrinology InternalMedicine MedicalWeightLoss

25/03/2026

- Semaglutide at ₹200/shot? 💉 Read this before you switch.

Ozempic and Wegovy have lost their patent in India — and overnight, 50+ companies have flooded the market with generic semaglutide.

Sounds like great news, right?

As an obesity & Metabolic Specialist who has been prescribing GLP-1 therapy for years, here’s what concerns me:

🔬 Semaglutide is NOT a simple tablet — it’s a peptide drug made using recombinant DNA technology. Not every company can manufacture this reliably.

🧊 Cold chain is everything. This drug must stay at 2–8°C from factory to your fridge. One break in Indian summer heat = degraded, ineffective medicine.

📊 Ozempic/Wegovy have 10+ years of clinical trial data — SUSTAIN, STEP, SELECT trials — with millions of patients studied worldwide. Most generics have completed just one Phase III trial in India.

⚠️ Companies that have NEVER manufactured injectables are now launching semaglutide brands. That’s a red flag.

So what should you do?

✅ DON’T self-switch — talk to your doctor
✅ WAIT 1–2 months for real-world quality data to emerge
✅ Your doctor will guide you to the RIGHT brand at the RIGHT time

Cheaper is welcome. But in peptide medicine, quality is non-negotiable.

Save this post. Share it with someone considering the switch. 💾

Ozempic Wegovy GenericSemaglutide ObesityMedicine Endocrinology DiabetesCare WeightLossJourney SemaglutideIndia GLP1ReceptorAgonist

16/03/2026

Truly humbled and deeply honoured to be invited to serve on the International Committee of RSSDI (Research Society for the Study of Diabetes in India).

RSSDI represents the largest professional body in Asia dedicated to diabetes research and care, and being entrusted with the responsibility to contribute to its international collaborations and global engagement is something I never imagined for myself.

This is undoubtedly one of the biggest milestones of my professional journey, and I am profoundly grateful for the trust placed in me.

My sincere thanks to Dr. Anuj Maheshwari sir and the RSSDI leadership for this opportunity and responsibility.

I look forward to contributing meaningfully to India’s growing voice in global diabetes and metabolic research.

—
Dr. Vinayak S. Hiremath

GlobalHealth
DiabetesCare

International Collaboration, Diabetes, Obesity!

10/03/2026

🚨 1 in 6 pregnancies worldwide is affected by Gestational Diabetes.

Most women don’t even know they have it.
Today is 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗚𝗲𝘀𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗗𝗮𝘆 — March 10.

Gestational Diabetes (GDM) is when blood sugar rises for the first time during pregnancy due to hormonal insulin resistance from the placenta. It often has ZERO symptoms — and the only way to catch it is a simple blood test.

Left untreated, it can cause:
⚠️ Large baby & difficult delivery
⚠️ Pre-eclampsia (dangerous high BP)
⚠️ Neonatal hypoglycemia
⚠️ 50% lifetime risk of Type 2 Diabetes for the mother

But here’s the 𝗚𝗢𝗢𝗗 𝗡𝗘𝗪𝗦 👇
With early diagnosis and proper management — diet, activity, glucose monitoring, and insulin if needed — most mothers go on to have a completely healthy pregnancy and baby. 95%+ cases resolve after delivery.

𝗘𝘃𝗲𝗿𝘆 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝘁 𝘄𝗼𝗺𝗮𝗻 𝘀𝗵𝗼𝘂𝗹𝗱 𝘂𝗻𝗱𝗲𝗿𝗴𝗼 𝗢𝗚𝗧𝗧 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗮𝘁 𝟮𝟰–𝟮𝟴 𝘄𝗲𝗲𝗸𝘀.

High-risk women should be screened in the 1st trimester itself.

🛡️ Protect two lives with one test.
Swipe through the carousel to learn everything — from risk factors to OGTT diagnostic criteria to the 4 pillars of GDM management.

Save this post. Share it with every pregnant woman and family you know. Tag your OB-GYN. This information can literally change outcomes.

💬 Have questions about GDM? Drop them in the comments — I’ll answer them personally.

📍 Dr Vinayak Hiremath

09/03/2026

Grateful to be part of EDEC 2026, Dubai.

An inspiring gathering of clinicians, researchers, and thought leaders discussing the future of endocrinology and metabolic health.

Always energizing to exchange ideas, learn from global experts, and bring those insights back to clinical practice.

EDEC2026

Dubai PhysicianLife ContinuousLearning DiabetesReversal DiabetesRemission GLP- 1, Mounjero, Ozempic, Wegovy

08/03/2026

Behind every strong family is a healthy woman. Yet women’s health is often the most neglected.

To the women who nurture families, lead communities, and inspire generations, today we celebrate your strength, resilience, and grace.

Wishing every incredible woman a very Happy International Women’s Day.

Let us also remember: prioritising women’s health is not a luxury, it is a necessity.

From diabetes and thyroid disorders to obesity and hormonal health, empowering women with knowledge and care is the true path to wellness.

— Dr. Vinayak Hiremath

Women’s health awareness| Hormonal health in women
PCOS | thyroid| diabetes in women | Metabolic health for women

Address

KMK HOSPITAL, KMK Junction, NORTH PARAVUR, ERNAKULAM
Kochi
683513

Opening Hours

Monday	9am - 8pm
Tuesday	9am - 8pm
Wednesday	9am - 8pm
Thursday	9am - 8pm
Friday	9am - 8pm
Saturday	9am - 2pm

Telephone

+919074563508

Website

https://drvinayakhiremath.exlyapp.com/

Alerts

Be the first to know and let us send you an email when Dr Vinayak S Hiremath posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr Vinayak S Hiremath:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Kochi?